Another focus of our research is drug repurposing for cancer immunotherapy. While drug repurposing (the use of already approved drugs in novel indications) has a long history in oncology, it has so far not been studied sufficiently in cancer immunotherapy. We have identified 40 drugs with broad anti-cancer activity that we hypothesize to also harbour the potential to lead to increased activation or proliferation of immune effector cells. We are currently screening these drugs in various in vitro settings with the goal of identifying drugs that possess both anti-cancer activity and immune-stimulating properties. We then want to test these drugs in vitro and in vivo as part of novel combination regimens.